Table 1.

Actual and relative titers of VSV-G and BASV-G pseudotype infections in various cell lines and primary cells^a

Cell line	Mean VSV-G titer (TU/ml) ± SD	Mean BASV-G titer (TU/ml) ± SD	Mean relative titer ± SDb
Human adherent cell lines
293T	1.2E+07 ± 3.7E+06	9.0E+06 ± 1.2E+05	74.5 ± 1.1
Huh-7	4.8E+06 ± 5.5E+05	4.3E+06 ± 2.1E+04	89.8 ± 0.4
A549	4.6E+06 ± 8.8E+04	3.2E+06 ± 3.1E+04	69.3 ± 0.7
HeLa	4.1E+06 ± 3.4E+05	2.8E+06 ± 1.8E+05	68.2 ± 4.4
SW480	2.9E+07 ± 5.8E+05	2.8E+07 ± 4.7E+05	95.1 ± 1.6
CaCo-2	7.2E+06 ± 8.1E+04	8.4E+06 ± 4.9E+05	116.7 ± 6.7
HT1080	8.8E+07 ± 2.1E+06	1.9E+07 ± 4.5E+06	21.6 ± 5.1
RD	1.3E+07 ± 7.4E+05	2.0E+07 ± 1.0E+04	153.9 ± 0.1
Human suspension cell lines
H9	1.4E+06 ± 3.7E+04	1.9E+05 ± 1.1E+04	13.1 ± 0.8
Jurkat	1.2E+07 ± 3.2E+05	6.1E+05 ± 1.8E+05	5.1 ± 1.5
B-THP	5.1E+07 ± 2.9E+06	5.7E+05 ± 2.1E+05	1.1 ± 0.4
THP-1	1.0E+06 ± 2.1E+05	5.8E+04 ± 3.6E+03	5.6 ± 0.3
HEL	1.4E+07 ± 1.8E+06	2.7E+06 ± 2.5E+05	19.3 ± 1.7
Vertebrate cell lines
Vero	3.9E+06 ± 7.9E+05	8.7E+05 ± 1.5E+05	22.5 ± 3.8
MC57	4.6E+06 ± 1.4E+06	2.4E+06 ± 1.5E+05	53.5 ± 3.2
NIH 3T3	3.2E+07 ± 7.8E+05	2.8E+05 ± 1.8E+04	0.9 ± 0.1
C6	4.8E+06 ± 3.3E+05	3.6E+05 ± 1.5E+05	7.5 ± 3.2
NRK	1.5E+07 ± 8.7E+04	2.8E+06 ± 1.2E+04	18.5 ± 0.1
BHK	7.0E+06 ± 2.2E+05	3.0E+06 ± 1.1E+04	42.7 ± 0.2
SK-RST	5.2E+06 ± 1.1E+04	2.3E+05 ± 5.5E+04	4.4 ± 1.0
MDBK	3.0E+06 ± 3.9E+05	4.0E+05 ± 2.9E+04	13.5 ± 1.0
Tb1Lu	5.0E+06 ± 4.8E+05	3.9E+05 ± 9.8E+04	7.8 ± 2.0
Invertebrate cell lines
C7/10	6.9E+07 ± 1.0E+07	7.4E+06 ± 5.7E+04	10.7 ± 0.1
C6/36	8.4E+07 ± 2.8E+05	6.1E+06 ± 1.3E+05	7.2 ± 0.2
Human primary cells
HUVEC	1.5E+07 ± 1.4E+06	6.5E+06 ± 6.1E+05	43.3 ± 6.1
HUPEC	1.1E+07 ± 1.1E+06	2.6E+06 ± 4.4E+05	23.6 ± 4.0

^aFor the negative control, the background level of infectivity of bald particles was 5.6E+03 ± 1.4E+03 TU/ml.

^bRelative titer is the BASV-G/VSV-G ratio as a percentage of VSV-G.